# Track 1: Clinical Phenotype, Molecular Hypothesis, and BUB1B Annotation Review in GENCODE v50

## 1. Starting Point: The Clinical Case

The official Track 1 case concerns **Mosaic Variegated Aneuploidy (MVA)**, a condition characterized by the presence of cell populations with abnormalities in chromosome number.

The phenotype provides the starting point for guiding genomic analysis. Rather than interpreting variants in isolation, the objective is to prioritize genes whose biological functions may be related to the cellular mechanisms involved.

## 2. Biological Hypothesis: Mitotic Spindle Regulation

Accurate chromosome segregation during mitosis depends on cell-cycle control mechanisms and the mitotic spindle. Alterations in genes involved in these processes represent a relevant research direction for investigating phenotypes associated with aneuploidy.

Within this context, **BUB1B** is a candidate of interest. This gene encodes the BUBR1 protein, which participates in the spindle assembly checkpoint. A functionally significant disruption of this system may compromise the fidelity of chromosome segregation.

For this reason, BUB1B is considered a molecular hypothesis worth investigating in the context of the case. This biological rationale guides the investigation but does not, by itself, establish that the gene explains the specific case.

## 3. Verification of BUB1B Annotation in GENCODE v50

As part of the genomic analysis preparation, the GENCODE v50 GTF file was inspected to verify how the candidate gene BUB1B is identified and annotated.

The inspection recorded the following characteristics:

| Field | Observed result |
|---|---|
| Gene symbol | `BUB1B` |
| GENCODE identifier | `ENSG00000156970.15` |
| Chromosome | `chr15` |
| Observed genomic interval | `40160984–40221137` |
| Interval length | `60154 bp` |
| Annotated gene type | `protein_coding` |
| Additional annotations | Multiple associated entries, including transcripts and UTR regions |

Among the inspected records is transcript `ENST00001082077.1`, named `BUB1B-221` and classified as `nonsense_mediated_decay`.

This label describes the transcript classification in the GENCODE annotation. It does not, by itself, demonstrate that a variant in the case causes RNA degradation or functionally alters the protein.

The inspection documents the identification of BUB1B and its genomic interval in the GTF file used. According to the inspection record, neither the GTF nor the VCF was modified during this procedure.

**Scope:** This inspection does not independently confirm the presence of a specific variant in the VCF, its pathogenicity, or a causal relationship with MVA.

## 4. Research Question

The guiding research question is:

> Does the case VCF contain variants in BUB1B that, when examined for technical quality, genomic location, and potential molecular consequences, may provide evidence consistent with the hypothesis derived from the phenotype?

This question structures the transition from clinical information to variant analysis and characterization.

## 5. Genomic Investigation Strategy

The analysis is organized into the following stages:

1. **Clinical context:** Record the official diagnosis and formulate a hypothesis based on the biological functions of candidate genes.
2. **Genomic exploration:** Examine the VCF and prioritize regions or variants warranting more detailed review.
3. **BUB1B review:** Compare the genomic interval identified in GENCODE v50 with the actual VCF records and retrieve variants observed in the region.
4. **Technical validation:** Record the position, reference and alternate alleles, genotype, and quality metrics for each candidate variant.
5. **Functional characterization:** Compare reference alleles against the GRCh38 reference sequence, consult the GENCODE annotation, and examine whether variants occur in coding sequences (CDS), untranslated regions (UTRs), exons, or intronic regions.
6. **Transcript verification:** Identify the transcript used for annotation and verify that the reported molecular consequences correspond to that reference.
7. **Evidence assessment:** Review the consistency of functional annotations, quality metrics, and allele phase when available and relevant to the hypothesis.

Identifying a gene in a GTF file, observing a variant in a VCF, and interpreting its potential effect are distinct steps. Each requires specific, reproducible evidence.

## 6. Role of TriNova.OS Balanced Ternary Representation

The ternary layer of TriNova.OS can be used as an exploratory representation of nucleotides and as a means of organizing or prioritizing information during analysis.

However, ternary representations and metrics do not, by themselves, constitute evidence of pathogenicity. They also do not establish that a variant causes the phenotype or replace genomic data validation, functional annotation, or clinical assessment.

## 7. What Can Be Concluded and What Remains to Be Verified

The biological relationship between MVA, chromosome segregation, and BUB1B function justifies investigating this gene. Inspection of GENCODE v50 documents how the gene is identified and annotated in the reference file used.

Nevertheless, these observations do not demonstrate that a BUB1B variant causes the specific case.

To document a potential connection with the case, the following points must be verified at a minimum:

- The actual presence of each candidate variant in the VCF.
- The genomic position and agreement of the VCF reference allele (REF) with the reference sequence.
- The genotype and quality metrics.
- The genome assembly version and transcript used for annotation.
- The molecular consequence and its consistency with the sequence and transcript.
- Allele phase, if the proposed hypothesis depends on variants affecting both chromosomes.
- The clinical and genetic evidence required to interpret the variant's relevance.

**Hypothesis status:** BUB1B is a biologically justified candidate for investigation based on the MVA phenotype. Identifying the gene in GENCODE v50 constitutes an annotation check, not causal validation. Confirmation of specific variants and their relevance to the case must be supported by reproducible genomic analysis results and the available clinical evidence.

## 8. Relationship to the Rest of the Repository

This document brings together the clinical reasoning, formulation of the molecular hypothesis, and initial verification of BUB1B annotation.

- `03_vcf_genomic_analysis/`: Technical VCF analysis, retrieval of candidate variants, and assessment of their genotypic characteristics, quality metrics and Final submission materials, if this directory is part of the repository structure..
- `04_gencode_audit/`: Review of transcripts, functional annotations, and potential annotation discrepancies.


This separation makes it possible to distinguish three fundamental elements:

1. **What the phenotype suggests:** The biological hypothesis guiding the investigation.
2. **What the data show:** VCF records and reference annotations that have been verified.
3. **What the evidence supports:** An interpretation grounded in reproducible checks, without confusing a hypothesis with an established causal relationship.
